Literature DB >> 23831374

Mortalin mutations are not a frequent cause of early-onset Parkinson disease.

Karen Freimann1, Katja Zschiedrich, Norbert Brüggemann, Anne Grünewald, Heike Pawlack, Johann Hagenah, Katja Lohmann, Christine Klein, Ana Westenberger.   

Abstract

Dysfunctional mitochondria and the mitochondrial chaperone mortalin (HSPA9, GRP75) have been implicated in the pathogenesis of Parkinson disease (PD). We screened 139 early-onset PD (EOPD) patients for mutations in mortalin revealing one missense change (p.L358P) that was absent in 279 control individuals. We also found one additional missense variant among the controls (p.T333K). Although both missense changes were predicted to be disease causing, we detected no differences in subcellular localization, mitochondrial morphology, or respiratory function between wild-type and mutant mortalin. These findings suggest that variants in mortalin (1) are not a major cause of EOPD; (2) occur in patients and controls; and (3) do not lead to functional impairment of mitochondria.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Early-onset Parkinson disease; GRP75; HSPA9; Mitochondria; Mortalin

Mesh:

Substances:

Year:  2013        PMID: 23831374     DOI: 10.1016/j.neurobiolaging.2013.05.021

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  9 in total

Review 1.  Mitochondrial chaperones in human health and disease.

Authors:  Tyler Bahr; Joshua Katuri; Ting Liang; Yidong Bai
Journal:  Free Radic Biol Med       Date:  2021-11-12       Impact factor: 7.376

Review 2.  Insights Into the Role of Mortalin in Alzheimer's Disease, Parkinson's Disease, and HIV-1-Associated Neurocognitive Disorders.

Authors:  Pankaj Seth
Journal:  Front Cell Dev Biol       Date:  2022-07-04

3.  Heat shock proteins in neurodegenerative disorders and aging.

Authors:  Rehana K Leak
Journal:  J Cell Commun Signal       Date:  2014-09-11       Impact factor: 5.782

Review 4.  Molecular chaperones and neuronal proteostasis.

Authors:  Heather L Smith; Wenwen Li; Michael E Cheetham
Journal:  Semin Cell Dev Biol       Date:  2015-03-12       Impact factor: 7.727

Review 5.  Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.

Authors:  Erik L Friesen; Mitch L De Snoo; Luckshi Rajendran; Lorraine V Kalia; Suneil K Kalia
Journal:  Parkinsons Dis       Date:  2017-08-21

Review 6.  Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease.

Authors:  Sandra Franco-Iborra; Miquel Vila; Celine Perier
Journal:  Front Neurosci       Date:  2018-05-23       Impact factor: 4.677

Review 7.  Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's disease.

Authors:  Baptiste Texier; Morgane Prime; Djamaa Atamena; Pascale Belenguer; Marion Szelechowski
Journal:  Neural Regen Res       Date:  2023-02       Impact factor: 6.058

8.  Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1.

Authors:  L F Burbulla; J C Fitzgerald; K Stegen; J Westermeier; A-K Thost; H Kato; D Mokranjac; J Sauerwald; L M Martins; D Woitalla; D Rapaport; O Riess; T Proikas-Cezanne; T M Rasse; R Krüger
Journal:  Cell Death Dis       Date:  2014-04-17       Impact factor: 8.469

9.  SNPs in SNCA, MCCC1, DLG2, GBF1 and MBNL2 are associated with Parkinson's disease in southern Chinese population.

Authors:  Aonan Zhao; Yuanyuan Li; Mengyue Niu; Guanglu Li; Ningdi Luo; Liche Zhou; Wenyan Kang; Jun Liu
Journal:  J Cell Mol Med       Date:  2020-07-11       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.